The Molbio Diagnostics IPO opened for public subscription on August 10, 2026, as Molbio Diagnostics launched its ₹939.70 crore mainboard public issue on BSE and NSE, as publicly reported on 2026-08-10. The book-built issue carries a price band of ₹768 to ₹807 per equity share and is scheduled to close for subscription on August 12, 2026. Allotment is expected to be finalised on August 13, 2026, with shares tentatively set to list on both exchanges on August 17, 2026.
Quick Highlights
- Founders: Sriram Natarajan, Chandrasekhar Bhaskaran Nair
- Book Running Lead Managers (BRLMs): Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited
- Anchor Investors: International Finance Corporation (IFC), HDFC Asset Management Company, and 31 other institutional investors — raising ₹281.46 crore at an anchor price of ₹807 per share on August 7, 2026
- Headquarters: Goa, India
- Announcement Date: August 10, 2026
- Price Band: ₹768–₹807 per equity share
- Lot Size: 18 shares (minimum investment of ₹14,526 at upper price band)
- Issue Composition: Fresh issue of ₹200 crore + Offer for Sale (OFS) of up to 91,66,000 equity shares
Funding Breakdown
Use of Funds
The company plans to deploy the net proceeds from the fresh issue of ₹200 crore across two primary capital expenditure heads. First, it will fund the setting up of infrastructure for a research and development facility, a Centre of Excellence, and connected office space to be operated by its wholly owned subsidiary, Bigtec. Second, the proceeds will fund the purchase of plant, machinery, and other equipment for its manufacturing units — specifically Goa Unit I, Goa Unit II, and its Visakhapatnam Unit. Any remaining proceeds will be applied toward general corporate purposes. The company will not receive any proceeds from the OFS portion; those funds will go directly to the selling shareholders.
Funding Timeline
Incorporated in October 2000, Molbio Diagnostics has raised a total of approximately $124 million across four funding rounds prior to this IPO, as publicly reported. The current ₹939.70 crore public issue represents its first listing on Indian stock exchanges and marks its transition from a privately funded enterprise to a publicly traded company on both BSE and NSE.
Expansion Plans
The IPO proceeds will directly support Molbio Diagnostics’ plans to scale its manufacturing capacity across its Goa and Visakhapatnam facilities, and to establish a dedicated R&D Centre of Excellence through its subsidiary Bigtec. The company already operates six manufacturing sites in India and supplies its products to over 90 countries through government health programmes, diagnostic laboratories, hospitals, and international healthcare companies — a global reach it aims to further consolidate through these infrastructure investments, as publicly reported.
Significance
The Molbio Diagnostics IPO is a landmark event for India’s point-of-care molecular diagnostics sector, bringing a company with a globally deployed proprietary platform — the Truenat system — into the public markets for the first time. The company reported revenue of ₹1,455.17 crore in FY2026, up from ₹1,027.94 crore in FY2025, and a net profit of ₹164.14 crore, reflecting consistent financial growth ahead of the listing. Strong pre-IPO institutional interest — with 33 anchor investors committing ₹281.46 crore, including IFC and leading domestic mutual funds — signals significant confidence from both global and domestic institutional capital in India’s diagnostics infrastructure story. The listing positions Molbio alongside established listed healthcare players and could catalyse further public market interest in deep-tech, point-of-care health companies headquartered outside India’s metro startup hubs.
These details have been verified against multiple publicly available reports as of 2026-08-10.
Stay updated with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
